Publishing: November 2021 | Report Code: LS11370 | Available Format: PDF
Metabolomics Market Overview
The global metabolomics market is projected to achieve a lucrative growth rate during the forecast period due to the increased government and private funding in research and development, and rise in metabolic application in personalized medication. The market is led by instruments, in terms of size, majorly attributable to the fact that metabolomics instrument is extensively used while following the various steps of the experimental protocol. Metabolomics bioinformatics tools and services are expected to witness the faster growth in future, as it facilitates simpler analysis and data interpretation of widely available biological data.
Metabolomics has wide application in various field, these include biomarker discovery, drug discovery, toxicology testing, nutrigenomics, functional genomics, personalized medicine, and others. The biomarker discovery was the largest application area of metabolomics in 2016, due to to the rise in prevalence of chronic diseases on the global level. Additionally, the extensive oncological research with inclination towards study of new biomarkers and its cancer application drives the larger contribution of biomarker discovery in the market.
Among different clinical indication, cancer is the largest contributor to the metabolomics market. This is mainly due to the global rise in prevalence of cancer, and the increasing oncological research activities. According to the World Health Organization (WHO), cancer has been the second leading cause of deaths globally, and accounted for 8.8 million deaths in 2015. Other clinical indications for metabolomics are cardiovascular disorders, neurological disorders, inborn errors of metabolism and others.
North America is the largest market for metabolomics products and services, mainly due to the factors such as presence of large number of funding from government and private bodies, and availability to technologically advanced products, with the dominance of some of the key players in the region. Asia-Pacific is expected to witness the fastest growth for the metabolomics market during forecast period. The major factors driving its growth are increasing healthcare and R&D expenditure, rise in adoption of technology for clinical applications, and the growing focus of major players to explore the untapped market.
Metabolomics Market Dynamics
Growth Drivers & Restraints
Various factors leading to the growth of the metabolomics industry include the rise in funding for technological research from government as well as private organizations, along with increase in collaborations & partnerships of key players for enhancement of their product portfolio. There has been significant rise in the R&D expenditure by the key players for development of technologically advanced metabolomics platforms, which is expected to drive the growth of the market during the forecast period. The advent of personalized medication also acts as a driving force to the growth of the market.
However, factors such as, data reprocessing and validation, and also the high prices of the tools and equipment are hindering the growth of the market. The market is also facing challenges like skilled labour to understand and resolve the complexity within biological samples.
The metabolomics industry provides immense opportunities to key players to explore the untapped market in the developing economies. Additionally, the wide array of upcoming research in the field of biomarkers development also provides immense opportunities for the growth of the global metabolomics market.
Metabolomics Market Competitive Landscape
The key players have been focused in the enhancement of their product portfolio, by forming partnerships. to increase metabolomics market share.
For instance, in June 2017, Thermo Fisher Scientific Inc. (Thermo Fisher) and Biocrates Life Sciences AG announce the launch of a ready-to-use kit for accurate metabolic phenotyping on high resolution mass spectrometry instruments. Under the co-marketing agreement, both the companies will jointly promote and market the combined use of the kit and Thermo Fisher's Q Exactive high-resolution, accurate-mass (HRAM) platform of mass spectrometers.
In July 2017, Thermo Fisher Scientific Inc. and SRI International, announced the results of their collaboration to enhance small molecule research. The results of the agreement enable researchers to combine the results of high-resolution Orbitrap LC/MS experiments with highly curated, and organism-specific metabolic pathway and genome data for quick and effective mass spectrometry-based small molecule research and analysis.
Some of the other key players in the global market include Agilent Technologies, Inc., Danaher Corporation, Waters Corporation, Shimadzu Corporation, Bio-Rad Laboratories, Inc., Bruker Corporation, Human Metabolome Technologies Inc., Metabolon, Inc.
Metabolomics Market Segmentation
By Product & Services
By Clinical Indication
Get a bespoke market intelligence solution
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws